Propanc Biopharma Engages European CDMO for GMP Manufacture of PRP Ahead of Phase 1b Oncology FIH Study

Propanc Biopharma's engagement of a European CDMO for GMP manufacture of its lead asset, PRP, signals the transition from preclinical development into clinical supply chain readiness, a stage where process development decisions and regulatory filing timelines become operationally binding. The company plans to submit a clinical trial application later in 2026, targeting a Phase 1b first-in-human study enrolling 30 to 40 patients with advanced solid tumors.

The unnamed CDMO offers end-to-end services covering cell line generation, banking and characterization, analytical development, process development, and drug substance and drug product batch production. Its stated expertise spans plasmid DNA and recombinant proteins, capability sets directly relevant to the biological complexity of PRP, a fixed combination of trypsinogen and chymotrypsinogen administered intravenously once weekly at dose levels informed by non-clinical safety and tolerability data.

For QA directors and CMC leads evaluating this program, the recombinant protein classification places PRP squarely within the scope of ICH Q11 development and manufacture of drug substances, with cell line characterization and comparability protocols likely to feature prominently in the clinical trial application dossier. The shift from a suppository formulation, used in compassionate use data published in Scientific Reports, to an IV route at significantly higher doses introduces additional sterility assurance and formulation development requirements that the CDMO selection will need to address.

Compassionate use data from that published study recorded a meaningful life extension in 19 of 46 terminal patients across a range of solid tumor types, without severe or serious adverse events attributed to treatment. The planned Phase 1b doses are described as substantially higher, calibrated against non-clinical safety findings to establish a safe starting dose in humans, a standard requirement under 21 CFR Part 312 and the EU Clinical Trials Regulation for FIH oncology studies.

PRP holds Orphan Drug Designation from the FDA for pancreatic cancer, granted in 2017, a status that carries implications for manufacturing exclusivity periods and may inform the regulatory strategy for the European clinical trial application filing.

The clinical trial application filing, targeted for later in 2026, will serve as the first formal regulatory checkpoint for the GMP manufacturing package assembled with the European CDMO.

Source: Propanc Biopharma, Inc. via GlobeNewswire, May 19, 2026.